Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ute Eisenberger, MD"'
Autor:
Malte Ziemann, MD, Monika Lindemann, MD, Michael Hallensleben, MD, Wolfgang Altermann, MD, Karina Althaus, MD, Klemens Budde, MD, Gunilla Einecke, MD, Ute Eisenberger, MD, Andrea Ender, PhD, Thorsten Feldkamp, MD, Florian Grahammer, MD, Martina Guthoff, MD, Christopher Holzmann-Littig, MD, Christian Hugo, MD, Teresa Kauke, MD, Stephan Kemmner, MD, Martina Koch, MD, Nils Lachmann, PhD, Matthias Marget, PhD, Christian Morath, MD, Martin Nitschke, MD, Lutz Renders, MD, Sabine Scherer, MD, Julian Stumpf, MD, Vedat Schwenger, MD, Florian Sommer, MD, Bernd Spriewald, MD, Caner Süsal, MD, Daniel Zecher, MD, Falko M. Heinemann, PhD, Murielle Verboom, PhD
Publikováno v:
Transplantation Direct, Vol 10, Iss 9, p e1680 (2024)
Background. Preformed donor-specific HLA antibodies (DSA) are a well-known risk factor in kidney transplantation. There is still considerable debate, however, about the optimal risk stratification among patients with preformed DSA. Additionally, data
Externí odkaz:
https://doaj.org/article/a67c56e5a200414ea670b837dd582929
Autor:
Wilfried Gwinner, MD, Annika Karch, PhD, Jan H. Braesen, MD, Abedalrazag A. Khalifa, MD, Jochen Metzger, PhD, Maarten Naesens, MD, Elisabet Van Loon, MD, Dany Anglicheau, MD, Pierre Marquet, PhD, Klemens Budde, MD, Mareen Matz, PhD, Wolfgang Arns, MD, Michael Fischereder, MD, Antje Habicht, MD, Ute Eisenberger, MD, Anja Mühlfeld, MD, Martin Busch, MD, Michael Wiesener, MD, Irina Scheffner, PhD,, Armin Koch, PhD
Publikováno v:
Transplantation Direct, Vol 8, Iss 5, p e1316 (2022)
Background. Timely recognition and treatment of acute kidney graft rejection is important to prevent premature graft failure. A predefined urinary marker set for acute T cell–mediated rejection (TCMR) containing 14 peptides was tested for this purp
Externí odkaz:
https://doaj.org/article/b3e9ed446cae4b729c75c1e914a62033
Autor:
Ute Eisenberger, MD, Justa Friebus-Kardash, MD, Hana Guberina, MD, Andreas Kribben, MD, Oliver Witzke, MD, Katharina Willuweit, MD, Guido Gerken, MD, Kerstin Herzer, MD
Publikováno v:
Transplantation Direct, Vol 5, Iss 1, p e419 (2019)
Background. Direct-acing antiviral agents are highly efficient treatment options for chronic hepatitis C virus (HCV) infection after renal allograft transplantation. Treatment options for patients with impaired graft function remain limited. Therefor
Externí odkaz:
https://doaj.org/article/375c016efacd4f11aac5ed8e216869f8